"Health Canada approves Novartis’ Fabhalta for PNH with haemolytic anaemia" was originally created and published by ...

Valentine’s Day represents a perfect opportunity to highlight news and updates from across biopharma that have hearts a | ...

A crucial challenge in AI today is bridging the gap between general intelligence and deep, organisation-specific knowledge.

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® (iptacopan capsules) as ...

The Trump administration's decision to pause enforcement of an anti-bribery law raised the specter that drugmakers could ...

Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...

Yuhan Corporation announced on the 11th that the allergy drug candidate "YH35324," introduced from GI Innovation, has demonstrated superior therapeutic effects compared to Novartis' "Xolair ... Class ...

The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel ...

Revenue was $263.4 million and $59.2 million for the year and quarter ended December 31, 2024, respectively, compared with ...

To boost its cardiovascular pipeline, Novartis has announced the acquisition of the company it co-founded with Blackstone ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...